US Stock Insider Trading | Tempus AI disclosed 15 insider transactions on February 20

K-LinePoet · 2026-02-22T01:20:40+00:00

On February 20, 2026, Tempus AI disclosed multiple internal transactions, including shareholder Eric Lefkofsky, who owns more than 10%, selling several stocks including 95,600 shares on February 19, involving a total amount of $7,046,000. The company focuses on applying artificial intelligence to the medical field.

K-LinePoet

2026-02-22 01:20:40

Abstract generation in progress

On February 20, 2026, Tempus AI (TEM) disclosed 15 insider transactions. Shareholder holding more than 10%, LEFKOFSKY ERIC P, sold 95,600 shares on February 20, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 20, 2026	Executive	Phelps Erik	February 19, 2026	Sell	5,650	59.05	333,600
February 20, 2026	Executive	Bartolucci Ryan M	February 19, 2026	Sell	2,902	59.05	171,400
February 20, 2026	Executive	Fukushima Ryan	February 19, 2026	Sell	9,592	59.05	566,400
February 20, 2026	Executive	Rogers James William	February 19, 2026	Sell	10,100	59.05	595,500
February 20, 2026	Shareholder with >10%	LEFKOFSKY ERIC P	February 19, 2026	Sell	13,600	59.05	802,300
February 20, 2026	Shareholder with >10%	LEFKOFSKY ERIC P	February 19, 2026	Sell	119,300	59.04	7,046,000
February 20, 2026	Shareholder with >10%	LEFKOFSKY ERIC P	February 19, 2026	Sell	42,300	58.31	2,464,700
February 20, 2026	Shareholder with >10%	LEFKOFSKY ERIC P	February 19, 2026	Sell	4,639	59.70	276,900
February 20, 2026	Executive	Polovin Andrew	February 19, 2026	Sell	8,143	59.05	480,800
February 20, 2026	Executive	Phelps Erik	February 19, 2026	Sell	3,814	60.00	228,800

[Company Information]

Tempus AI, Inc. was founded by Eric Lefkofsky, initially incorporated in Delaware in August 2015 under the name Bioin LLC. On August 7, 2025, the company was restructured from a Delaware corporation to a Nevada corporation through a conversion. The company is dedicated to creating intelligent diagnostics through artificial intelligence (AI) in healthcare, unlocking the true power of precision medicine. They connect laboratory results with patients’ own clinical data to make testing smarter and results personalized.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.